Micafungina Mylan

Micafungin, the active ingredient in Micafungina Mylan, is an echinocandin antifungal presented as an intravenous injection for intravenous use. It treats invasive candidiasis, esophageal candidiasis, candidemia and is used for prophylaxis of fungal infections in hematopoietic stem cell transplantation.

GNH USA supplies Micafungina Mylan as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Micafungin is an echinocandin antifungal used to treat serious Candida infections and to prevent fungal disease in high‑risk patients.

- Invasive candidiasis: eradicates bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: resolves mucosal infection and associated pain. - Candidemia: clears bloodstream Candida infection. - Prophylaxis in hematopoietic stem cell transplantation: prevents invasive fungal infection during neutropenia.

Micafungin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Infusion‑related reactions (flushing, rash, pruritus). - Elevated liver enzymes (ALT, AST). - Nausea. - Diarrhea. - Headache. - Fever.

Serious or Rare Side Effects: - Hepatotoxicity (significant liver injury). - Severe hypersensitivity reactions (anaphylaxis, Stevens‑Johnson syndrome). - Renal impairment. - Hematologic abnormalities (thrombocytopenia, neutropenia).

When using Micafungina Mylan, clinicians should consider several safety measures.

- Renal function: monitor serum creatinine in patients with pre‑existing kidney disease. - Hepatic function: assess liver enzymes before and during therapy. - Drug interactions: review concomitant medications that affect CYP3A4. - Pregnancy and lactation: use only if benefits outweigh risks, as safety data are limited. - Patient monitoring: observe for signs of infusion reactions and hepatic toxicity. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce micafungin exposure. - Cyclosporine: increased micafungin levels, risk of toxicity. - Concomitant use with other echinocandins: additive toxicity. - High‑dose azoles (e.g., voriconazole): may increase micafungin concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR. - Statins metabolized by CYP3A4 (e.g., simvastatin): monitor for myopathy. - Immunosuppressants (e.g., tacrolimus): adjust dosing as needed.